Few details were provided on the program that Boehringer will now pick up but Kyowa Kirin’s Chief Medical Officer Takeyoshi Yamashita, Ph.D., said the compound was developed in-house by the Japanese pharma company, according to a Friday release (PDF).
The Kyowa Kirin deal is Boehringer’s smallest of the week and the third in as many days. The German pharma signed a T-cell anticancer therapy partnership with 3T Biosciences on Thursday, which could hit $538.5 million altogether.
Praxis Precision Medicines is also heading to Asia for its next partnership in a deal with Tenacia Biotechnology (Shanghai) Company, according to a Friday release. The CNS disorder biotech has handed over rights to the essential tremor medicine ulixacaltamide in Greater China in exchange for $15 million upfront, a $10 million investment in common stock and an additional $264 million in milestones. Royalties on sales will also be possible.
Ulixacaltamide is a small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical, which transmits information between the cerebellum and thalamus.